MedTrace Logo

Precise Treatment in Hepatobiliary Cancers (PTHBC)

NCT02715089 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2016-03-22

No results posted yet for this study

Summary

The purpose of this study is to explore the precise treatment in hepatobiliary cancer patients and evaluate drug safety, progression free and overall survival. This trial study is based on genetic tests, then therapeutic target drugs are administered according to the genetic test reports. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit from precise treatment which targets particular genetic abnormality. The identifications of these genetic abnormalities may help treat hepatobiliary cancer patients better.

Conditions

  • Liver Neoplasms
  • Biliary Tract Neoplasms
  • Hepatobiliary Neoplasms

Interventions

GENETIC

Precise treatment

During screening stage, all patients should accept next-generation sequencing (NGS) test.

Sponsors & Collaborators

  • 3D Medicines

    collaborator INDUSTRY

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Hai-Tao Zhao, Doctor · Peking Union Medical College Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2017-12-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02715089 on ClinicalTrials.gov